In the transfer of obligations for a double-blind, multi-center trial, a sponsor has maintained the task of creating the randomization schedule. Who at the sponsor company should create the randomization schedule?
In a double-blind clinical trial, the randomization schedule must be generated by an independent biostatistician not directly involved in study operations or data management to preserve study blinding and integrity.
According to ICH E9 and the GCDMP (Chapter: Regulatory Requirements and Compliance), randomization generation and blinding must be handled in a way that prevents bias or unintentional unblinding of study personnel. The sponsor's biostatistician not assigned to the project (Option C) is the appropriate person because they have the necessary statistical expertise but remain operationally independent from study execution.
A project biostatistician (Option D) or programmer (Option A) directly involved in data analysis could inadvertently compromise blinding. The CRO biostatistician (Option B) should not perform this function if the sponsor retains randomization responsibility.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Regulatory Requirements and Compliance, Section 6.4 -- Randomization and Blinding
ICH E9 -- Statistical Principles for Clinical Trials, Section 5.4 -- Randomization Procedures and Blinding
FDA Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics, Section 4.3 -- Maintaining Blinding Integrity
Nu
9 hours agoJerry
6 days agoAn
11 days agoGlory
16 days agoSolange
21 days agoJesse
26 days agoAlyce
1 month agoKris
1 month agoZack
1 month agoChi
2 months agoReynalda
2 months agoPaola
2 months agoKatie
2 months agoIsaiah
3 months agoMilly
3 months agoSharee
3 months agoNida
2 months agoOra
2 months agoTayna
3 months ago